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INTRODUCTION
Do we need another study on anemia and erythro-
poiesis-stimulating agents in hemodialysis?
The effectiveness of erythropoiesis-stimulating agents (ESAs)
to correct renal anemia has been one of the great advance-
ments in the last 2 decades of renal replacement therapy (RRT)
(1). Quality of life of patients on RRT has improved substantially
with the advent of ESAs (2, 3), and a major reduction in the
need of blood transfusions is an undeniable, concrete benefit
of ESA therapy. However, even after intense research on ESAs
and their use to achieve an optimal hemoglobin (Hb) target
capable of improving patient outcome, some key points are yet
to be clarified (4), as was recently underlined by some recent
trials (5, 6) and a meta-analysis (7). 
The need for optimal ESA use is amplified by the fact that
these agents are quite expensive. In the United States, e.g.,
expenditures for ESAs have doubled from $0.9 billion to $1.9
billion over the last 5 years, whereas the overall level of expen-
diture for care has remained stable. As health care budgets are
not endlessly expandable, greater use of ESAs will necessarily
compete with health care expenditures related to other poten-
tially interesting treatments or drugs. In some countries, it
might result in limited availability of ESAs or other drugs, or in
the restriction of the use of certain drugs to specified patient
groups. A scenario where the introduction of newer agents
such as cinacalcet, or support for important strategies like set-
ting up screening programs for chronic kidney disease (CKD),
or educational programs on CKD for general practitioners, are
barred by governments or health care providers appears not
unrealistic. Thus the increased expenditure needed to achieve
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higher Hb target can be afforded by national health sys-
tems only if it is counterbalanced by a clear benefit.
We as a nephrology community have an important respon-
sibility in maintaining the appropriate usage of these
agents. It is fundamental that our community provides data
proving that indeed we do make best use of the money
spent, to avoid having financing bodies themselves impose
rules on us for how we use these agents. Until now, exten-
sive recent data on the nature and extent of parameters
causing overusage or inappropriate usage of ESAs in CKD
stage 5 patients are lacking. Available observational stud-
ies have focused mainly on the degree of achievement of
Hb correction, rather than on a mechanistic or in-depth
analysis of the relation between dose of ESA and Hb level
achieved, or these studies date from the pre-guidelines era
(8-10). The ESAM study (11), published shortly after the
development of the European Best Practice Guidelines
(EBPG) on anemia management (12), demonstrated that in
2003, only 66% of patients achieved the goals set by the
EBPG. Also in the Dialysis Outcomes and Practice
Patterns Study (DOPPS) (9), it was apparent that only
around 60% of the patients surveyed in different European
dialysis centers achieved recommended Hb levels. More
importantly, whereas observational studies give us a clue
regarding how many patients achieve the targets, they
leave us unaware of the underlying “efforts” in terms of
ESA dosage used to obtain these Hb levels. It is striking
that in DOPPS, e.g., the dosage of ESA used in the United
States was twice that of European centers, despite the
achievement of the same hemoglobin levels (9). In addition
to a likely different burden of comorbidities between the 2
populations, there appear also to be policy-related factors
besides so-called patient-related hyporesponsiveness fac-
tors that have a substantial impact on the usage of ESAs.
A well-performed observational study is thus needed to ana-
lyze factors that lead to inefficient ESA use. This will proba-
bly help not only in identifying those patients who are more
likely to benefit from higher Hb targets, but also to rationalize
ESA expenditures and thus reduce the cost of treatment.
A second problem relating to the use of ESAs is the recom-
mended level of correction. Recent randomized controlled
trials (RCTs) found no significant effect (6) or even a higher
mortality risk in patients randomized to complete anemia
correction (5). This has raised concern that the upper level
of the Hb target (e.g., 13 g/dL) is too high, as can be seen
in the latest revision of the Kidney/Dialysis Outcomes
Quality Initiative (K/DOQI), which will propose reducing the
level to 12 g/dL. However, circumstances in RCTs of CKD
stages 3 and 4 and end-stage renal disease (ESRD) cannot
be simplistically equated to those encountered in everyday
clinical practice. To start with, it is quite striking that the
mortality in large RCTs is far below that observed in non-
study populations. For example, in a RCT on the effect of
correction of lipid disturbances in diabetic dialysis patients
in Germany (the 4D study) by Wanner et al (13), the mortali-
ty observed in the intervention group was not different from
that observed in the placebo group, but was only half that
observed in the general German dialysis population. The
same holds true for the Cardiovascular Risk Reduction by
Early Anemia Treatment with Epoetin Beta (CREATE) trial
(6): in which, after a mean follow-up of approximately 3
years, 105 patients had had a first cardiovascular event.
This cardiovascular event rate was only half the rate to be
expected. The selection effects of RCTs together with the
impact of being studied seem to distort the “real” effect of
interventions and hamper the generalizability of study
results to broad patient populations. This suggests at least
that some factors relating to general care of ESRD patients
are not satisfactorily taken care of in everyday practice (14).
In this regard, it is of interest that in the quality assessment
part of DOPPS, some centers do perform well on a particu-
lar parameter A, but not on B, whereas others perform well
on parameter B but not on A, and that only a very limited
number of centers comply with all investigated quality
assessment parameters (15). For these reasons, an obser-
vational study that registers all practices related to anemia
management on a large (European) scale, and which allows
us to link this to achieved clinical outcomes – defined as
ESA use, anemia correction obtained and mortality/morbid-
ity outcome – can give important information to unravel the
hidden factors determining differences between good and
less good clinical practice. In addition, we hope and believe
that merely the fact of registering the parameters for a
benchmarking goal might already, just as in a clinical trial,
have a positive impact. 
A second problem is that in randomized controlled trials,
patients should reach a given Hb concentration according
to their randomization arm. This might lead to the situation
that some patients who would normally not obtain a full
correction of their anemia to, let’s say, an Hb of 13 g/dL, are
“forced” with all means available to obtain this goal, where-
as in everyday clinical practice, the clinician would have
been satisfied with an Hb of 11.5 g/dL. Forced treatment
targets may expose patients with a frail cardiovascular con-
ditions and/or diabetes to an unwarranted high-risk level. In
the meta-analysis by Phrommintikul et al (7), the 2 trials that
found an increased mortality risk with randomization to nor-
mal Hb levels enrolled a much higher percentage of diabet-
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ics compared with the other trials included in the analysis. 
A third problem, which applies to both RCTs and everyday
clinical practice, is that there is a difference between aiming
toward and actually achieving a certain Hb level. It is impos-
sible to exactly predict the Hb level that will be obtained in a
patient after a certain ESA dose, so we will always end up
with a range – with a mean value and with a standard devia-
tion of, let’s say, 0.5 g/dL. If we set 12 g/dL as the desirable
Hb level to be achieved in all patients, this means that to
have 97.5% of patients above 12 g/dL, we are bound to
accept a mean Hb value of 13 g/dL, and also that 50% of
the population will be between 13 and 14 g/dL. In addition,
once we achieve a certain Hb level with ESA treatment, this
level will not be stable over time. Indeed, drifting and undu-
lating of Hb levels have recently been recognized as a pos-
sible factor influencing patient outcome (16). However, no
RCT has yet taken this issue into account. 
A last problem of RCTs is that patients should be equal in
all parameters, except 1 – the intervention. However, it is
clear that in medicine, and especially in patient groups
with a high burden of comorbidity, only a few factors do
have so strong an effect on their own that they can make
a real difference in outcome. It is thus no real surprise to
see that it is difficult to obtain significant differences in
outcome if you are only allowed to have 1 parameter that
is different between 2 groups. Once again, it appears that
the picture obtained by a well-balanced observational
study might be more realistic than that seen through the
myopic glasses of a randomized controlled trial.
For all these reasons, we believe that a large European
registry of anemia management in hemodialysis patients,
and the factors relating to underachievement of targets in
this regard, both at the patient level (hyporesponsiveness)
and at the center level (anemia management policies) is
still of great importance. 
STUDY PROPOSAL FOR STRATEGIES
FOR ANAEMIA CORRECTION AND USE
OF ERYTHROPOIESIS-STIMULATING AGENTS
IN DIALYSIS PATIENTS
A cross-sectional prospective observational study 
This first study proposes to evaluate, in a multicenter
cross-sectional observational study, the prevalence and
distribution of anemia and its treatment in a large
European dialysis population. In the participating units, all
patients treated by dialysis (hemodialysis [HD] and peri-
toneal dialysis [PD]) for at least 6 months will be evaluat-
ed. During a 2-month observation period including 3 mea-
surements, treatment by erythropoiesis-stimulating agents
(ESAs) and parameters potentially related to ESA hypore-
sponsiveness and underachievement of anemia correction
at center level will be investigated. Routine center policies
for anemia surveillance and management and administra-
tive regulations will also be recorded. As part of a quality
management program, the same evaluation will be repeat-
ed after 1 year in the same centers.
Introduction
Anemia is a common and well-recognized problem in
patients with ESRD on dialysis. Over the last 2 decades,
treatment of renal anemia has been substantially improved
by the introduction of ESAs. Whereas treatment with ESAs
is quite effective in correcting Hb levels in most patients,
still some important problems remain. To start with, ESAs
are quite expensive, which limits their availability in some
countries. Existing data suggest that doses needed to
obtain “normal” Hb levels (>12 g/dL) are exponentially
higher than those needed to obtain the lower Hb levels
(between 10 and 12 g/dL) characterized by some studies
to be beneficial.
In addition, it is clear that some patients need far larger
doses of ESAs to achieve a target Hb level than others,
and for some patients, even with very high doses of ESA,
no correction of Hb can be obtained. For these patients,
defined as ESA-resistant (>300 U/kg per week), malnutri-
tion and inflammation, in addition to comorbidities, have
been proposed as important factors influencing response
to ESA. However, little is known still about the epidemiolo-
gy of ESA hyporesponsiveness in Europe, and its causes
have not been yet fully elucidated. The need to optimize
the use of ESAs is evident. As a nephrology community,
facing a constant growth in dialysis and predialysis popula-
tions, there is a responsibility to optimize the use of ESAs
to make the cost of therapy sustainable in the future.
Aim of the project
1. Identify the relative contribution of different factors that
hamper optimal correction of anemia in dialysis
patients by investigating
- the prevalence and distribution of anemia in a large
European dialysis population;
- the degree of anemia correction obtained and the
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use and dosage patterns of ESAs;
- the prevalence of ESA hyporesponsiveness (i.e.,
>300 U/kg per week) (considered as a continuous
and as a categorical variable) and its underlying
causes at patient level;
- the factors that may explain differences in anemia
correction and/or ESA hyporesponsiveness at a
national, regional and/or center level.
2. Set up an instrument that will allow us to improve ane-
mia management at the individual patient and center
level.
It is anticipated that, as part of a quality improvement pro-
gram, the return of the results to the participating centers
will also allow each of them to optimize their anemia man-
agement at the levels of individual patient and center care.
Therefore, the same evaluation will be conducted after 1
year in the same participating centers.
Study design
This QUEST (QUality European STudies) project is a cross-
sectional observational study that will register the follow-
ing, in all dialysis patients treated in the participating units: 
- anemia parameters (retrospectively, for months –1 and
0, and prospectively at month +1) and doses of ESA
and iron given (total doses given during 4 weeks from
month -1 to 0, and 0 to 1) (Fig. 1);
- comorbidities and parameters potentially related to
ESA hypo-responsiveness;
- center policies for anemia management during the
investigated period.
After 12 months, the time 0 evaluation will be repeated in
the same centers according to the same inclusion and
exclusion criteria. 
Center and patient inclusion criteria
Based on the nationalities of the Anaemia Working
Group members (Tab. I), units of each of the 12 repre-
sented countries will be included in the study (plus
Germany and Austria, and extension of Estonia to the
Baltic States and of Finland to the Scandinavian coun-
tries). This geographical partition represents a balance
between western and central Europe and includes most
of its large countries. The target number for inclusion of
patients is 3,500. 
For each participating country, a list of dialysis centers
should be made available to the study group. A stratified
randomization of centers will be performed to obtain a
representative participation of university, large regional
and small regional centers. In each center, all patients
should be included in the study. 
The working group members will act as study counsel-
lors at the national level and verify the time schedule at
the participating units. 
In addition, a part-time study coordinator and a part-time
data(base) manager will be hired. 
Each participating center should commit itself to include
all its patients treated by dialysis (HD and PD) for at least
6 months. In return, they will receive 20 euros per com-
pleted patient file.
Local ethics committee approval and patient informed
consent forms may be requested depending on the
national and/or local regulations. In cases where an
informed consent form is mandatory at the local level,
the number of patients refusing to participate should not
exceed 10% of the total number of treated patients. If
this percentage is exceeded, another center should be
asked to participate. 
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Fig. 1 - Time chart for records and measurement of anemia parameters. 
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Study protocol
Parameters to register:
A. Individual patient data
1. Demographic data
- Sex
- Ethnicity
- Age
- Weight, height
- Type of renal disease (according to EDTA Registry
coding)
- Diabetes: yes/no 
- Time on dialysis: months
- Dialysis modality (HD vs. hemodiafiltration [HDF] vs.
PD)
2. Hematologic data
- Hemoglobin and reticulocyte count at the beginning
of the months -1, 0 and +1 (midweek predialysis
sample for hemodialysis patients and 3 values
measured during the last – if possible, monthly –
consultations for PD patients)
3. Potential causes of ESA resistance:
- Iron storage parameters: ferritin, serum iron and
serum transferrin (to calculate transferrin saturation)
- Serum albumin (+ determination method in center
questionnaire)
- C-reactive protein (CRP)
- Intact parathormone (PTH) level (last measured
value, <6 months before study)
- Kt/V urea (last measured value, <3 months before
study): for HD, value/session; for PD, value/week
- Residual renal function (last measured creatinine
clearance in ml/min)
- Type of hemodialysis access: arteriovenous shunt,
polytetrafluoroethylene graft, biological graft, tran-
sient or permanent catheter
- Aggravating clinical factors during the preceding 3
months: infection, malignancy, episodes of bleed-
ing, surgery, hospitalization etc.
4. Therapeutic data 
- Use of ESA: yes/no
1. agent: epoetin-alpha, epoetin-beta, darbepoetin,
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TABLE I
QUEST–ANAEMIA WORKING GROUP MEMBERS
Clinical area experts Country Position E-mail address
F. Locatelli Italy Chair nefrologia@ospedale.lecco.it
M. Martins Prata Portugal Co-chair martins.prata@hsm.min-saude.pt
J.P. Wauters Switzerland Co-chair Jean-Pierre.Wauters@insel.ch
L. Del Vecchio Italy Secretary luciadelvecchio@yahoo.com
W. Van Biesen Belgium Secretary wim.vanbiesen@ugent.be
J. Arrieta Spain jarrieta@hbas.osakidetza.net
C. Bovy Belgium cbovy@yahoo.com
A. Debska-Slizien Poland adeb@amg.gda.pl
K. Leunissen The Netherlands kle@sint.azm.nl
A. MacLeod United Kingdom mmd175@abdn.ac.uk
J. Mauri Spain nefrologia@htrueta.scs.es
K. Metsärinne Finland kaj.metsarinne@tyks.fi
G. Mircescu Roumania gmircescu@hotmail.com
K. Siamopoulos Greece ksiamop@cc.uoi.gr
E. Villar France emmanuel.villar@chu-lyon.fr
A. Wiecek Poland awiecek@spskm.katowice.pl
E. Will United Kingdom Eric.Will@leedsth.nhs.uk
Registry experts
C. Gronhagen-Riska Finland carola.gronhagen-riska@hus.fi
M. Ots Estonia Mai.Ots@kliinikum.ee
V. Stel ERA/EDTA Registry v.s.stel@amc.uva.nl
other …
2. total administered dose during two 4-week peri-
ods (months –1 to 0 and 0 to 1) (raw
units/weights; a conversion factor for darbepoet-
in-alpha will be applied centrally )
3. administration route: subcutaneous or intra-
venous
4. administration frequency: days/week or
days/month
5. start of ESA : <3 months, between 3 and 6
months, >6 months before data collection
- Iron administration: yes/no
1. agent: saccharate, dextran, gluconate, other …
2. total administered dose over each of the two 4-
week periods
3. administration route: intravenous or peroral
4. administration frequency: days/week or
days/month, on demand
- Units of transfused packed cells during the months
–1 and 0
- Oral anticoagulants: yes/no
- Platelet inhibitors: yes/no
- Angiotensin-converting enzyme inhibitors and/or
angiotensin receptor blockers: yes/no
B. Center data
1. Center policy 
- Recommended type and mode of ESA administra-
tion
- Type of guidelines followed or presence of specific
center policies
- Use of iron storage parameters and dosage; iron
administration and policy in interval prior to serum
iron parameter sampling
- Routine vitamin C and/or folic acid administration
- Management of anemia parameters on a daily
basis: nephrologist, dialysis nurse, dedicated nurse
2. Use of management software tools and/or database
3. National/regional policy for ESA prescription 
4. National/regional policy for ESA reimbursement
Statistical analysis
Statistical analysis will include 
1. descriptive analysis of the data, at the individual cen-
ter, country and European levels (mean and/or median,
with 25th and 75th percentiles, as appropriate)
2. comparisons of relevant subgroups according to sex,
dialysis modality, access type, ESA agent, route of
administration of ESA, country etc. These analyses will
be performed by t-test, Mann-Whitney test or 1-way
ANOVA, as applicable.
3. univariate and multivariate regression analysis of differ-
ent continuous variables (Hb, ESA dose, age, months
on dialysis, iron parameters, CRP, residual renal func-
tion, PTH) with ESA dose, and Hb levels achieved.
To avoid interference with “loading dose” problems,
patients treated with ESA for less than 6 months will be
analyzed separately.
For all statistical investigations and their results, it will be
kept in mind that these should be considered as hypothe-
ses generating associations, and that these may not be
causal.
APPENDIX
*QUEST Anemia Study Group: C. Zoccali and K. Jager (QUEST
co-chairs), F. Locatelli (chair), M. Martins Prata (co-chair), J.P.
Wauters (co-chair), L. Del Vecchio (secretary), W. Van Biesen
(secretary), A. Dębska-Ślizień, J.M. Mauri, K. Metsärinne, G.
Mircescu, K.C. Siamopoulos, V.S. Stel, E. Will (members).
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